Fedha

Hisa unazofuatilia
Mtazamo: Thamani itaongezeka kwa asilimia 28.0·Thamani itapungua kwa asilimia 4.0
Nenda kwenye kichupo cha uchanganuzi
GSK:NYSE
GSK plc
US$ 48.58
-1.36%
(-0.67) Siku 1
US$ 48.58
0.00% (0.00)
Baada ya saa
Imefungwa: 18 Nov, 16:00:02 GMT -5  ·   USD
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya GSK...
Fungua
US$ 49.03
Juu
US$ 49.49
Chini
US$ 48.54
Mtaji wa soko
98.33B
Wastani wa kiasi cha mauzo
4.82M
Kiasi cha mauzo ya hisa
2.20M
Gawio
3.78%
Mgawo wa faida wa kila robo mwaka
US$ 0.46
Tarehe ya kutojumuisha gawio
12 Nov 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
17.22
Juu kwa wiki 52
US$ 61.70
Chini kwa wiki 52
US$ 45.80
EPS
US$ 2.82
Beta
0.20
Hisa za wawekezaji
2.02B
Idadi ya wafanyakazi
elfu 67
Fungua
US$ 49.03
Juu
US$ 49.49
Chini
US$ 48.54
Mtaji wa soko
98.33B
Wastani wa kiasi cha mauzo
4.82M
Kiasi cha mauzo ya hisa
2.20M
Gawio
3.78%
Mgawo wa faida wa kila robo mwaka
US$ 0.46
Tarehe ya kutojumuisha gawio
12 Nov 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
17.22
Juu kwa wiki 52
US$ 61.70
Chini kwa wiki 52
US$ 45.80
EPS
US$ 2.82
Beta
0.20
Hisa za wawekezaji
2.02B
Idadi ya wafanyakazi
elfu 67
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Kuhusu GSK plc
Afisa Mkuu Mtendaji (CEO)Emma Walmsley | Emma Walmsley
Wafanyakazielfu 66.8
Lilianzishwa27 Des 2000
Makao makuu-
SektaHealth Care
Sekta-
Tovutigsk.com
Ukadiriaji wa mchanganuzi
Kulingana na wachanganuzi 2 waliotoa ukadiriaji wa hisa kwa GSK katika miezi 3 iliyopita
Nunua
Nunua
1
Shikilia
1
Uza
0
Utabiri wa miezi 12
Kulingana na wachanganuzi 2 wa Wall Street wanaotoa makadirio ya bei ya miezi 12 ya GSK katika miezi 3 iliyopita.
Juu kabisa
Ya sasa US$ 48.58
US$ 60.00 (+23.51%)
Wastani
US$ 57.95 (+19.29%)
Chini kabisa
US$ 55.90 (+15.07%)
Mchanganuzi
Unaopendekezwa
Kitendo
Bei lengwa
Unaokadiriwa
Tarehe
Michael Leuchten
Jefferies
Hold
Downgraded
US$ 55.90
+15.1%
10/28/2026
Unknown Analyst
Berenberg Bank
Buy
Upgraded
US$ 60.00
+23.5%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
US$ 70.00
+44.1%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Ripoti ya mwisho
28 Okt 2026
Kipindi cha Kifedha
Robo3 2026
£ 1.45 / £ 1.33
+9.46%umepitiliza
Mapato dhidi ya makadirio (GBP)
8.89B / 8.84B
+0.54%umepitiliza
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 3 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika GBP
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika GBP
Des 2025
Mac 2026
Jun 2026
Sep 2026
Mapato
8.62B
7.63B
8.41B
8.89B
Gharama ya bidhaa zilizouzwa
2.62B
1.87B
2.07B
2.24B
Gharama ya mapato
2.62B
1.87B
2.07B
2.24B
Gharama za utafiti na maendeleo
2.14B
1.52B
1.75B
1.90B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
2.67B
2.08B
2.19B
2.17B
Gharama ya uendeshaji
4.37B
2.99B
3.74B
4.06B
Jumla ya gharama za uendeshaji
6.99B
4.86B
5.81B
6.30B
Mapato ya uendeshaji
1.63B
2.77B
2.60B
2.59B
Mapato mengine yasiyo ya uendeshaji
-21.00M
-
-
-
EBT ikijumuisha vipengee visivyo vya kawaida
950.00M
2.14B
354.00M
1.94B
EBT bila kujumuisha vipengee visivyo vya kawaida
1.48B
2.62B
2.48B
2.39B
Gharama ya kodi ya mapato
223.00M
305.00M
-199.00M
232.00M
Kiwango cha kodi kinachotumika
23.47%
14.23%
-56.21%
11.99%
Gharama nyingine za uendeshaji
-434.00M
-615.00M
-204.00M
-17.00M
Mapato halisi
636.00M
1.74B
435.00M
1.54B
Kiwango cha faida halisi
7.38%
22.77%
5.17%
17.36%
Mapato kwa kila hisa
-
-
-
-
Mapato ya riba na uwekezaji
17.00M
22.00M
58.00M
29.00M
Gharama ya riba
-145.00M
-167.00M
-182.00M
-219.00M
Jumla ya gharama halisi za riba
-128.00M
-145.00M
-124.00M
-190.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
2.69B
3.23B
2.82B
3.33B
Faida au hasara kutokana na uuzaji wa vipengee
-40.00M
-
-
-
Miamala ya wajuzi wa mambo
Data ya miamala ya watu wenye hisa hutolewa kwenye vyanzo vya washirika wengine. Pata maelezo zaidi
Mjuzi wa mambo
Nafasi
Aina
Tarehe
Hisa
Kiasi
Ukurasa wa 1
Matukio yajayo
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google